Stocks · Healthcare · Biotechnology
Dianthus Therapeutics, Inc. DNTH
$88.21 -0.12% Close, Oct 2, 2026 · NASDAQ · Market cap $4.93B
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin narrowed to -11441.4% from -2676.6% a year earlier.
- The diluted share count rose 56.4% in a year.
- Revenue over the last four quarters was $1.9M, down 60.8% from a year earlier, accelerating from -79.5% a quarter earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 9%
- Revenue growth, 3-year CAGRBottom 5%
- Revenue growth accelerationTop 9%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 49%
- Gross marginTop 12%
- Operating marginBottom 3%
- Accruals (lower is better)Bottom 7%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 30%
- Free-cash-flow yieldTop 47%
- EBITDA / enterprise valueTop 39%
- Sales / enterprise valueBottom 2%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthTop 8%
- 6-month returnBottom 45%
- 1-year return vs S&P 500Top 11%
- Distance from 52-week highTop 40%
- Trend checklist (0–4)Top 39%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 29%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 10%
- Upside to consensus price targetBottom 42%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 37%
- Maximum drawdown, 3 yearsTop 27%
- Beta vs S&P 500 (lower is better)Top 33%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -79.5% | -60.8% | ↑ |
| Gross margin | 100.0% | 96.0% | ↓ |
| Operating margin | -2676.6% | -11441.4% | ↓ |
| FCF margin | -2067.6% | -8178.0% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -60.8% | -79.5% | ↑ | Bottom 9% |
| Gross margin | 96.0% | 100.0% | ↓ | Top 12% |
| Operating margin | -11441.4% | -2676.6% | ↓ | Bottom 3% |
| Net margin | -1570.9% | -2364.1% | ↑ | — |
| Free-cash-flow margin | -8178.0% | -2067.6% | ↓ | — |
| Return on invested capital | -18.5% | — | Top 49% | |
| Revenue growth, 3-year CAGR | -31.8% | — | Bottom 5% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 10.3%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 1800.0%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +232.6 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -1.31%
- Shareholder yield
- -1.31%
- Share count change, 1 year
- +56.4%
- Share count change, 3-year CAGR
- +145.4%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 3 of 8
- Average EPS surprise, last 4
- -9.4%
- Average 2-day reaction, last 8
- +2.8%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $126.83
- Target vs current price
- +43.8%
- Analysts with a rating
- 11
- Share rating Buy or Strong Buy
- 100%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | -6.3% | +4.1% | +5.5% | -0.4% | — |
| May 5, 2026 | +27.4% | +1.0% | -2.5% | -8.7% | +26.1% |
| Mar 9, 2026 | -45.9% | +21.5% | +19.4% | +31.1% | +25.1% |
| Nov 5, 2025 | -12.8% | +1.6% | +8.7% | +32.4% | +60.2% |
| Aug 7, 2025 | -2.3% | -6.1% | +2.3% | +20.9% | +65.5% |
| May 12, 2025 | +4.7% | +2.5% | +0.5% | -7.1% | +4.1% |
| Mar 11, 2025 | +4.7% | -3.9% | -9.7% | -35.9% | -26.2% |
| Nov 7, 2024 | -25.4% | +1.7% | -10.4% | -19.6% | -15.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | -$0.90 | -$0.85 | -6.3% | $761,000 |
| May 5, 2026 | -$0.85 | -$1.17 | +27.4% | $463,000 |
| Mar 9, 2026 | -$1.43 | -$0.98 | -45.9% | $284,000 |
| Nov 5, 2025 | -$0.97 | -$0.86 | -12.8% | $396,000 |
| Aug 7, 2025 | -$0.88 | -$0.86 | -2.3% | $193,000 |
| May 12, 2025 | -$0.82 | -$0.86 | +4.7% | $1.2M |
| Mar 11, 2025 | -$0.81 | -$0.85 | +4.7% | $1.3M |
| Nov 7, 2024 | -$0.74 | -$0.59 | -25.4% | $2.2M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 2533.99× | — | — | Bottom 2% |
| Free-cash-flow yield | -3.16% | — | — | Top 47% |
| Earnings yield | -0.15% | — | — | Top 30% |
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 283
- 50-day average slope (20 days)
- -0.2%
- 200-day average slope (20 days)
- +7.3%
- Distance from 50-day average
- -15.7%
- Distance from 200-day average
- +8.7%
- RSI (14)
- 29.7
- Relative volume
- 0.83×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 48.7%
- Volatility vs own 5-year history
- 4th percentile · Low for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.84
- Correlation with S&P 500
- 0.20
- Current drawdown from 1-year high
- -23.9%
- Maximum drawdown, 3 years
- -53.5%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 5, 2021 | Dec 29, 2022 | -97.5% | 439 days | Not yet recovered |
| Oct 13, 2020 | Nov 9, 2020 | -20.5% | 19 days | 29 days (Dec 21, 2020) |
| Feb 10, 2021 | Feb 18, 2021 | -15.8% | 5 days | 4 days (Feb 24, 2021) |
| Mar 10, 2021 | Mar 30, 2021 | -14.6% | 14 days | 3 days (Apr 5, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $4.93B
- EPS, diluted (TTM)
- -$0.13
- Revenue (TTM)
- $1.9M
- 52-week range
- $32.22 – $117.88
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Gross profit | $1.5M | $6.4M | $2.8M | $6.2M | $2.0M |
| Operating income | -$13.1M | -$29.7M | -$48.2M | -$101.9M | -$177.9M |
| Net income | -$13.1M | -$28.5M | -$43.6M | -$85.0M | -$162.3M |
| EPS (diluted) | -$3.82 | -$7.60 | -$8.45 | -$2.55 | -$4.20 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $1.3M | $1.2M | $193,000 | $396,000 | $284,000 | $463,000 | $761,000 |
| Net income | -$25.2M | -$28.4M | -$29.5M | -$31.6M | -$36.8M | $97.9M | -$40.8M | -$50.2M |
| EPS (diluted) | -$0.74 | -$0.81 | -$0.82 | -$0.88 | -$0.97 | $2.59 | -$0.85 | -$0.90 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$59.5M | -$29.1M | -$36.9M | -$78.2M | -$129.1M |
| Capital expenditure | -$1.3M | -$139,000 | -$110,000 | -$105,000 | -$213,000 |
| Free cash flow | -$60.8M | -$29.2M | -$37.0M | -$78.3M | -$129.3M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $89.6M | $0 | $72.0M | $269.2M | $280.1M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $886.8M
- Total assets
- $1.21B
- Total liabilities
- $41.2M
- Total debt
- $1.3M
- Net debt
- -$109.3M
- Shareholders’ equity
- $1.17B
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 8,829,663
- Days to cover
- 14.42
- Change vs previous report
- +4.7%
FINRA short interest, settlement date Sep 15, 2026.
Stock splits
- Sep 12, 2023
- 1-for-16